RAPORT ESPI 16/2023|02-06-2023|Dopuszczenie i wprowadzenie akcji Emitenta do obrotu giełdowego na rynku regulowanym prowadzonym przez GPW

Previous PostRAPORT KWARTALNY Q1 2023|30-05-2023| Skonsolidowany rozszerzony raport Scope Fluidics za I kwartał 2023 r.Next PostRAPORT ESPI 17/2023|12-06-2023|Podsumowanie działań w ramach Scope Discovery

0Shares

18.11.2024

Scope Fluidics Secures $30 Million from Conditional Payment Settlement with Bio-Rad Laboratories in Curiosity Diagnostics Sale

aj0

24.09.2024

Scope Fluidics Signs Agreement for IVDR Certification of Innovative BACTEROMIC System

lk0

04.09.2024

Notified Body Initiates IVDR Certification Readiness Assessment for BACTEROMIC System, Developed by Scope Fluidics Group

lk0

CONTACT US

Tel. +48 22 376 21 14
Email: biuro@scopefluidics.com

Address

Ogrodowa 58
9th floor
00-876 Warsaw

KRS: 0000668408

NIP: 527-264-59-89

REGON: 142-754-170

LEI: 259400EUNFX4E2BEHU15

Company registered in the District Court for the Capital City of Warsaw in Warsaw, XII Commercial Division of the National Court Register.

Share capital: PLN 272 593,00 fully paid up

Bank Account Number: 03 2490 0005 0000 4520 3046 2136

Życzenia

RAPORT ESPI 16/2023|02-06-2023|Dopuszczenie i wprowadzenie akcji Emitenta do obrotu giełdowego na rynku regulowanym prowadzonym przez GPW

Related Posts

Scope Fluidics Secures $30 Million from Conditional Payment Settlement with Bio-Rad Laboratories in Curiosity Diagnostics Sale

Scope Fluidics Signs Agreement for IVDR Certification of Innovative BACTEROMIC System

Notified Body Initiates IVDR Certification Readiness Assessment for BACTEROMIC System, Developed by Scope Fluidics Group